HAMBURG, Germany , Oct. 21, 2024 /PRNewswire/ -- Mediso is unveiling its new AnyScan® TRIO SPECT/CT, TheraMAX* scanner at the annual meeting of European Association of Nuclear Medicine (EANM). The new TheraMAX is specifically designed for serving the clinical needs of theranostic imaging.
It features detectors and collimators developed for Targeted Radionuclide Therapies carried out with radioisotopes emitting not only alpha and beta particles, but high and ultra-high energy gamma photons like 177 Lu, 212 Pb, 131 I, 225 Ac and beyond. The TheraMAX is equipped with three, large surface detectors (up to 5x larger than 12-detector CZT systems) surrounding the patients completely (360°). The 15.
9mm thick NaI crystals ensure improved sensitivity for high energy photons, while the high-density sensor arrangement (123 PMT per detector head) allows high spatial resolution leading to PET-like image quality in all NM applications. The 300% sensitivity gain compared to conventional dual-detector systems enables whole body 225 Ac SPECT/CT in theranostic imaging, while this extreme total system response also allowing ultra-fast quantitative total-body SPECT/CT scans with 99m Tc and LEHR-HS collimator. Moreover, novel multi-pinhole technology combined with Triple-NaI-Detectors provide outstanding performance for cardiology and neurology.
The integrated CT offers three performance levels: low-dose diagnostic scans, ultra-low dose protocol for attenuation and scatter correction and e.
